Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$134.29 USD
+1.21 (0.91%)
Updated Aug 15, 2024 10:04 AM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 261 - 280 ( 672 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Muscular Dystrophy BD Teams Might Want to Take Notice of the New Kid on the Block
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Muscular Dystrophy Toolbox Delivers Compelling Reads Across Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Alternative Take on SRP-9001; Bodes Well for Functional Benefits From Study Two
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2H19 Value Drivers Within Our Coverage Universe
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bears Get Another Victory Lap on a Seemingly Arbitrary CRL; Target Lowered to $160 to Reflect Near Term Uncertainty
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT
Provider: Stock Traders Daily
Analyst: Research Department